Oxford, UK based Greywolf Therapeutics is pursuing cancer and autoimmune indications by attempting to target T-cells at their first signal of activation - an approach the company leads the field on

Co-Founder and CEO Peter Joyce describes the science behind this, including how the company's lead programs inhibit Endoplasmic Reticulum Associated Proteases (ERAPs). A clinical stage company, he describes Greywolf's clinical experience and fundraising history.